Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$275.25 - $318.06 $390,304 - $451,009
1,418 New
1,418 $403,000
Q4 2022

Feb 14, 2023

BUY
$252.44 - $306.72 $367,805 - $446,891
1,457 New
1,457 $404,000
Q2 2022

Aug 12, 2022

BUY
$187.54 - $223.02 $436,780 - $519,413
2,329 Added 43.84%
7,641 $1.56 Million
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $101,435 - $130,359
453 Added 9.32%
5,312 $1.27 Million
Q3 2021

Nov 12, 2021

BUY
$282.99 - $369.05 $1.38 Million - $1.79 Million
4,859 New
4,859 $1.38 Million
Q4 2020

Feb 12, 2021

SELL
$236.26 - $355.63 $477,245 - $718,372
-2,020 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$264.77 - $305.71 $114,645 - $132,372
433 Added 27.28%
2,020 $573,000
Q1 2020

May 14, 2020

BUY
$268.85 - $341.04 $426,664 - $541,230
1,587 New
1,587 $502,000
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $431,097 - $595,673
-1,959 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$217.44 - $243.88 $32,181 - $36,094
-148 Reduced 7.02%
1,959 $457,000
Q2 2019

Aug 14, 2019

SELL
$219.29 - $241.72 $23,902 - $26,347
-109 Reduced 4.92%
2,107 $492,000
Q1 2019

May 14, 2019

BUY
$216.71 - $338.96 $94,485 - $147,786
436 Added 24.49%
2,216 $524,000
Q4 2018

Feb 14, 2019

BUY
$278.5 - $352.75 $495,730 - $627,895
1,780 New
1,780 $536,000
Q3 2018

Nov 14, 2018

SELL
$293.51 - $383.83 $498,086 - $651,359
-1,697 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$257.52 - $306.91 $253,399 - $301,999
984 Added 138.01%
1,697 $492,000
Q1 2018

May 14, 2018

BUY
$260.13 - $367.91 $23,671 - $33,479
91 Added 14.63%
713 $195,000
Q3 2017

Nov 14, 2017

SELL
$281.15 - $329.69 $29,520 - $34,617
-105 Reduced 14.44%
622 $195,000
Q2 2017

Aug 14, 2017

BUY
N/A
727
727 $197,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Srb Corp Portfolio

Follow Srb Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Srb Corp, based on Form 13F filings with the SEC.

News

Stay updated on Srb Corp with notifications on news.